Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amplia Therapeutics ( (AU:ATX) ) has issued an announcement.
Amplia Therapeutics has reported significant progress in its ACCENT trial, demonstrating a 31% response rate for its FAK inhibitor narmafotinib combined with chemotherapy, surpassing the 23% rate of chemotherapy alone. The company is also initiating a new trial combining narmafotinib with FOLFIRINOX chemotherapy in the USA and Australia, supported by a recent $27.5 million capital raise to fund operations through 2027.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is a company focused on developing innovative treatments for cancer and fibrosis, with a particular emphasis on small molecule focal adhesion kinase (FAK) inhibitors.
Average Trading Volume: 7,015,221
Technical Sentiment Signal: Buy
Current Market Cap: A$93.52M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.